BioSpace News Archive

IMV Inc. announced the pricing of its previously-announced underwritten public offering of 14,285,714 units at a price to the public of US$1.75 per Unit, for aggregate gross proceeds to the Corporation of approximately US$25 million, before deducting underwriting commissions and Offering expenses and excluding any proceeds the Corporation may receive from the exercise of the underlying warrants.

ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa’s Co-Founder, Chief Executive Officer, and Chairman, is an invited speaker at the 2nd Annual LifeSci Partners’ Virtual Private Company Summer Symposium.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada’s premier federally funded research organization, the National Research Council.

BetterLife Pharma Inc. is pleased to announce early positive in vitro results of its SARS-CoV-2 (“COVID-19”) anti-viral, recombinant human interferon alpha-2b (“rhIFN⍺2b” or “AP-003”), from the Dr. Stephen Barr Laboratory and state-of-the-art ImPaKT Facility at Western University (“UWO”). AP-003’s first proposed target indication is for people at higher risk to develop severe COVID-19 disease.

Shape Therapeutics Inc. today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital.

Harrow Health, Inc. (NASDAQ: HROW) an ophthalmic-focused healthcare company, today announced that the United States Patent and Trademark Office issued two Patents, No. US 10,993,921, B2, dated May 4, 2021, and No. US 11,045,432 B2, dated June 29, 2021, entitled “Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof.”

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2021 financial results and provide an update on the company’s business and outlook on Thursday, July 29, 2021 , at 4:30 p.m. (ET) after the closing of the market.

Incyte announced that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 3, 2021.

Moderna, Inc. today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 5, 2021 to report its second quarter 2021 financial results, and provide a corporate update.

LENSAR, Inc. today announced a total of 12 abstracts highlighting LENSAR’s technology have been accepted for presentation at the 2021 Annual Meeting of the American Society of Cataract and Refractive Surgery.